Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04308148 · ClinicalTrials.gov registry record
Does Medical Cannabis Reduce Opioid Use in Adults With Pain
A clinical trial, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- 217
- Enrollment target
NCT04308148: Completed study, sponsored by Albert Einstein College of Medicine.
NCT04308148 is a clinical trial that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 217 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04308148 has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- 217 participants
- Enrollment target
Study Summary
The study will examine how medical cannabis use affects opioid analgesic use. This landmark study will be among the first to examine the effect of medical cannabis with different THC/CBD (Tetrahydrocannibinol/Cannabidiol) content on opioid use as well as adverse events.
Primary Outcome
The primary outcome will be opioid analgesic use.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2020-10-06 |
| Est. Completion | 2024-03-13 |
What the finished NCT04308148 record still lists
NCT04308148 is an observational study that tracks outcomes without assigning an intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04308148 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04308148 about?
NCT04308148 is a clinical study titled "Does Medical Cannabis Reduce Opioid Use in Adults With Pain". The study will examine how medical cannabis use affects opioid analgesic use. This landmark study will be among the first to examine the effect of medical cannabis with different THC/CBD (Tetrahydrocannibinol/Cannabidiol) content on opioid use as well as adverse events.
What is the current status of trial NCT04308148?
This trial is currently completed. The enrollment target is 217 participants. The study started on 2020-10-06. Estimated completion is 2024-03-13.
Who is sponsoring clinical trial NCT04308148?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079282 · 217 participants · Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
- NCT05470439 · 217 participants · NA
My Interprofessional Care Team for Adherence and Research Engagement Disparities
- NCT05981703 · 217 participants · Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- NCT06342258 · 217 participants · Phase 1
COES: Curing Order Effects on Sealants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI